Neovasc Inc. (TSXV: NVC) today reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina. The COSIRA trial also confirmed that the Reducer is safe and well-tolerated, with no reports of device-related serious adverse events. The safety and efficacy data from the randomized, controlled COSIRA trial is consistent with results seen in previous non-randomized pilot studies of the Reducer.

Acusphere, Inc. (ACUSD.PK) today announced that William I. Ramage, D. Phil., has been appointed Chief Development Officer of the Company. Acusphere is focused on the development of Imagify™ (Perflubutane Polymer Microspheres for Injectable Suspension), which if approved for sale, will be a novel cardiovascular drug for the detection of coronary artery disease (CAD), the leading cause of death in the United States and Europe.

Senior nurse for speciality medicine Audrey Kirby was named Nurse Leader of the Year and the heart failure team came home with the Cardiovascular Service Award.

Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) allowing the company to initiate SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients. 

Memorial is pleased to announce the formation of a unique partnership with one of the area’s most well known centers for cardiovascular care – The Heart Institute of East Texas.

BIOTRONIK announced today that the PK Papyrus covered coronary stent system has received CE mark for the treatment of acute coronary artery perforation.

OrbusNeich today announced that new clinical data presented at TCT 2013 show durable outcomes as well as excellent early healing and optimal neointimal suppression out to 24 months following placement of the COMBO Dual Therapy Stent. These results from the EGO-COMBO Study were presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China, at the annual interventional cardiology conference in San Francisco.

A healthy weight is the key to a healthy heart, and yet an estimated 1 out of 3 children is either overweight or obese in the U.S. During a special symposium Oct. 27 at the American Academy of Pediatrics National Conference and Exhibition in Orlando, pediatricians discussed obesity and cardiovascular risk factors, public health policy, and how physicians can partner with families to improve children's weight.